{
    "clinical_study": {
        "@rank": "119432", 
        "acronym": "AZD3293DDI", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 AZD3293-itraconazole", 
                "arm_group_type": "Experimental", 
                "description": "Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole  will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14."
            }, 
            {
                "arm_group_label": "Group 2 AZD3293-diltiazem", 
                "arm_group_type": "Experimental", 
                "description": "Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14."
            }, 
            {
                "arm_group_label": "Group 3 AZD3293-midazolam", 
                "arm_group_type": "Experimental", 
                "description": "Subjects from Group 3 will receive a single dose of  midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of  midazolam will be administered. Group 3 subjects will be discharged on Day 18"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is  a single-center, open-label, 3-group, fixed-sequence drug-drug interaction\n      study to assess the effect of coadministration of multiple-dose itraconazole or diltiazem on\n      the single-dose PK of AZD3293 and the effects of coadministration of single- and\n      multiple-dose AZD3293 on the single-dose PK of midazolam.  The study will also evaluate the\n      safety and tolerability of single and multiple oral doses of AZD3293, alone and in\n      combination with itraconazole, diltiazem, and midazolam in healthy young subjects.AZD3293 is\n      being developed for the treatment of Alzheimer's disease"
        }, 
        "brief_title": "A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Pharmacologic Action"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed, written, and dated informed consent prior to any study-specific\n             procedures Male and nonfertile female healthy subjects, aged 18 to 55 years at the\n             time of consent\n\n          -  Body weight \u226550 to \u2264100 kg and body mass index (BMI) \u226519 to \u226430 kg/m2\n\n          -  Clinically normal findings on physical examination in relation to age, as judged by\n             the           Investigator\n\n          -  Male healthy subjects must be willing to use barrier contraception, ie, condoms, even\n             if their partners are post-menopausal, surgically sterile, or using accepted\n             contraceptive methods, from the first day of dosing until 3 months after the last\n             dose of investigational product (IP)\n\n        Exclusion Criteria:\n\n          -  Participation in any prior study of AZD3293\n\n          -  History of any clinically significant disease or disorder which, in the opinion of\n             the Investigator, may put the subject at risk because of participation in the study,\n             may influence the results, or may limit the subject's ability to participate in the\n             study\n\n          -  History or presence of gastrointestinal, hepatic or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism or excretion\n             of drugs\n\n          -  History of previous or ongoing psychiatric disease/condition including psychosis,\n             affective disorder, anxiety disorder, borderline state and personality disorder\n             according to the criteria in the Diagnostic and Statistical Manual of Mental\n             Disorders, 4th edition (DSM IV), as assessed by the Mini-International\n             Neuropsychiatric Interview (MINI)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02010970", 
            "org_study_id": "D5010C00004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1 AZD3293-itraconazole", 
                "description": "AZD3293 oral solution", 
                "intervention_name": "Group 1 AZD3293", 
                "intervention_type": "Drug", 
                "other_name": "beta secretase inhibitor"
            }, 
            {
                "arm_group_label": "Group 2 AZD3293-diltiazem", 
                "description": "AZD3293 oral solution", 
                "intervention_name": "Group 2 AZD3293", 
                "intervention_type": "Drug", 
                "other_name": "beta secretase inhibitor"
            }, 
            {
                "arm_group_label": "Group 3 AZD3293-midazolam", 
                "description": "AZD3293 oral solution", 
                "intervention_name": "Group 3 AZD3293", 
                "intervention_type": "Drug", 
                "other_name": "beta secretase inhibitor"
            }, 
            {
                "arm_group_label": "Group 1 AZD3293-itraconazole", 
                "description": "itraconazole capsule", 
                "intervention_name": "Group 1 Itraconazole", 
                "intervention_type": "Drug", 
                "other_name": "azole antifungal"
            }, 
            {
                "arm_group_label": "Group 2 AZD3293-diltiazem", 
                "description": "Diltiazem ER tablet", 
                "intervention_name": "Group 2 Diltiazem", 
                "intervention_type": "Drug", 
                "other_name": "calcium channel blocker"
            }, 
            {
                "arm_group_label": "Group 3 AZD3293-midazolam", 
                "description": "midazolam syrup", 
                "intervention_name": "Group 3 Midazolam", 
                "intervention_type": "Drug", 
                "other_name": "benzodiazepine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium Channel Blockers", 
                "Diltiazem", 
                "Midazolam", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "phase I", 
            "healthy volunteers", 
            "AZD3293", 
            "itraconazole", 
            "diltiazem", 
            "medazolam", 
            "drug interactions", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cypress", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers", 
        "overall_official": {
            "affiliation": "WCCT Global", 
            "last_name": "Apinya Vutikullird, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "In Group 1, serial blood samples for AZD3293 plasma concentrations will be collected from predose to 96 hours after administration of AZD3293 on Day 1 and from predose to 144 hours after study drug administration on Day 8. Sparse blood samples for itraconazole plasma concentrations will be collected at predose (prior to administration of AZD3293) on Day 1 and 2 hours after the morning dose of itraconazole on Day 5 through Day 13. In Group 2, serial blood samples for AZD3293 plasma concentrations will be collected from predose to 96 hours after administration of AZD3293 on Day 1 and from predose to 144 hours after study drug administration on Day 8. Sparse blood samples for diltiazem plasma concentrations will be collected at predose (prior to administration of AZD3293) on Day 1 and 3 hours after diltiazem administration on Day 5 through Day 13.", 
                "measure": "The effect of multiple-dose co-administration of CYP3A4 inhibitors on the single-dose PK of AZD3293 measured by assessment of area under the curve over the time (AUC) and maximum concentration", 
                "safety_issue": "No", 
                "time_frame": "up to day 13"
            }, 
            {
                "description": "Serial blood samples for midazolam plasma concentrations will be collected from predose to 24 hours after administration of midazolam on Day 1 and Day 17 and for 48 hours after administration of midazolam on Day 8. Sparse blood samples for AZD3293 plasma concentrations will be collected at predose (prior to administration of midazolam) on Day 1 and 2 hours after AZD3293 administration on Day 2 through Day 10.", 
                "measure": "The effect of multiple-dose AZD3293 administration (including the reversibilityof any of its effects) on the single-dose PK of a CYP3A4/CYP3A5 substrate (midazolam) by assessment of area under the curve over the time (AUC) and maximum concentration", 
                "safety_issue": "No", 
                "time_frame": "up to day 17"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02010970"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety profile in terms of Adverse events assessment", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline and up to day 18"
            }, 
            {
                "measure": "Safety and tolerability in terms of lab tests assessment (hematology, chemistry, urinalysis)", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline and up to day 18"
            }, 
            {
                "measure": "Safety and tolerability in terms of vital signs assessment (blood pressure, pulse and body temperature) and physical exams", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline and up till day 18"
            }, 
            {
                "measure": "Safety and tolerability by assessing changes in electrocardiogram (ECG) parameters", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline and up to day 18"
            }, 
            {
                "measure": "Safety and tolerability  by assessing telemetry records", 
                "safety_issue": "Yes", 
                "time_frame": "from baseline and up to day 13"
            }, 
            {
                "measure": "Suicidality mesured by Columbia-Suicide Severity Rating Scale (C-SSRS)", 
                "safety_issue": "Yes", 
                "time_frame": "from Baseline and up till day 18"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}